LAUREN QUAVE: Open Payments
NPI 1881960136 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,686 in 67 payments from 12 companies in 2025. Trend: 2023 $1,470 · 2024 $1,787 · 2025 $1,686
Food & beverage: $1,603Education: $83
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 20 | $408 |
| ViiV Healthcare Company | 14 | $384 |
| Merck Sharp & Dohme LLC | 8 | $181 |
| Astellas Pharma US Inc | 5 | $168 |
| Aimmune Therapeutics, Inc. | 2 | $134 |
| Melinta Therapeutics, LLC | 5 | $100 |
| ABBVIE INC. | 4 | $90 |
| Theratechnologies Inc. | 3 | $81 |
| Shionogi Inc | 2 | $62 |
| La Jolla Pharmaceutical Company | 2 | $45 |
Products named: CABENUVA, DOVATO, ZERBAXA, ZENPEP, Rezzayo, Cresemba, EGRIFTA, Fetroja.
Industry payments across MS — which companies pay providers there.
